ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings
  • Abstract Number: 2051 • ACR Convergence 2022

    Targeting Janus Kinase Pathway in Sjogren’s Disease Corrects IFN-Driven Inflammation and Epithelial Dysfunction

    Sarthak Gupta1, Eiko Yamada2, Hiroyuki Nakamura2, Zohreh Khavandgar3, Daniel Martin2, Mayank Tandon4, Ilias Alevizos5, Shyh-Ing Jang2, Paola Perez2, Kalie Dominick2, Thomas Pranzatelli2, Alan Baer6, john chiorini4 and Blake Warner3, 1National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Bethesda, MD, 2NIDCR, Bethesda, MD, 3National Institutes of Health, Bethesda, MD, 4NIH, Bethesda, MD, 5Horizon Therapeutics, Gaithersburg, MD, 6Johns Hopkins University School of Medicine, Baltimore, MD

    Background/Purpose: Many of the inflammatory cytokines implicated in Sjogren's Disease (SjD) pathogenesis, in particular Type I and II interferons (IFNs), signal through Janus kinases (JAK)…
  • Abstract Number: 2056 • ACR Convergence 2022

    Long Term Safety and Effectiveness of Belimumab Therapy in Patient with SLE: A Single Center Retrospective Analysis

    Takehiro Nakai1, Sho Fukui2, Takahiro Asano3, Futoshi Iwata4, Hiroki Ozawa5, Satoshi Kawaai4, Yukihiko Ikeda1, Hiromichi Tamaki1, Mitsumasa Kishimoto6, Kenichi YAMAGUCHI7 and Masato Okada1, 1St. Luke's International Hospital, Tokyo, Japan, 2Kyorin University Hospital, Tokyo, Japan, 3St. Luke's International Hospital, Chuo City Tokyo, Japan, 4St. Luke's International Hospital, Chuo-ku, Tokyo, Japan, 5Immuno-Rheumatology Center, St.Luke's International Hospital, Tokyo, Japan, 6Kyorin University School of Medicine, Yokohama, Japan, 7St.Luke's International Hospital, Tokyo, Japan

    Background/Purpose: Many clinicians use belimumab as a maintenance therapy of SLE, but there is scarce data on belimumab drug retention rate and safety/effectiveness profile in…
  • Abstract Number: 2050 • ACR Convergence 2022

    Stratification on Baseline Interferon Scores and Use of CRESS to Improve the Design of Future Trials in Sjögren’s Syndrome: Post Hoc Analysis from a Randomized Controlled Trial

    jacques-eric gottenberg1, Bryan Downie2, Oksana Gurtovaya2 and Anubhav Mathur2, 1Strasbourg University Hospital, Strasbourg, France, 2Gilead Sciences, Foster City, CA

    Background/Purpose: A multicenter, global, randomized, Phase 2, double-blind, placebo (PBO)-controlled study showed filgotinib (FIL; 200 mg/d), lanraplenib (LAN; 30 mg/d), and tirabrutinib (TIRA; 40 mg/d)…
  • Abstract Number: 2054 • ACR Convergence 2022

    Towards a Novel Clinician-Reported Outcome Measure for SLE – Outcomes of an International Consensus Process

    Kathryn Connelly1, Laura Eades2, Rachel Koelmeyer3, Darshini Ayton3, Vera Golder2, Rangi Kandane-Rathnayake2, Kate Gregory-Wong3, Hussein Al-Mossawi4, Jeanette Andersen5, Cynthia Aranow6, Laurent Arnaud7, Anca Askanase8, Subhashis Banerjee9, Catherine Barbey10, Hermine Brunner11, Joy Buie12, Laurie Burke13, Alain Cornet14, Karen Costenbader15, Maria Dall'Era16, Khadija Dantata17, Nikolay Delev9, Ann Eldred18, Alan Friedman19, Richard Furie20, Sandra Garces21, Dennis Grasela22, Heath Guay23, Oliver Guenther24, Maria Juarez25, Shelly Kafka26, Kenneth Kalunian27, Elaine Karis28, Youmna Lahoud29, Catharina Lindholm30, Jeffrey Lockman31, Charlotte Lupton32, Justine Maller33, Ashley Marion34, Patrick Marquis35, Joan Merrill36, Thomas Morel37, Marta Mosca38, Yulia Pincus39, Samantha Pomponi40, Guillermo Pons-Estel41, Jorge Ross Terres33, Cailin Sibley42, Maria Silk43, Sanjeev Roy44, Lee S Simon45, Alessandro Sorrentino46, Christian Stach47, George Stojan48, Ying Sun24, Yoshiya Tanaka49, Erik Thomas50, Ronald van Vollenhoven51, Cristina Vazquez Mateo50, Edward M Vital52, Victoria Werth53, Eric Zollars28, Qing Zuraw54 and Eric Morand55, 1Monash Health, Camberwell, Australia, 2Monash University, Clayton, Australia, 3Monash University, Melbourne, Australia, 4AstraZeneca, Bucks, United Kingdom, 5Lupus Europe, Lupus DK, EULAR PARE, ERN ReCONNECT, Brussels, Belgium, 6Feinstein Institutes for Medical Research, Manhasset, NY, 7Hautepierre Hospital, University Hospital of Strasbourg, Rheumatology, Strasbourg, France, 8Columbia University Medical Center, New York, NY, 9Bristol Myers Squibb, Princeton, NJ, 10Biogen, Baar, Switzerland, 11Division of Rheumatology, Cincinnati Children's Hospital Medical Center, University of Cincinnati, Department of Pediatrics, Cincinnati, OH, 12Lupus Foundation of America, Charleston, SC, 13LORA Group, Royal Oak, MD, 14Lupus Europe, Brussels, Belgium, 15Brigham and Women's Hospital, Boston, MA, 16University of California, Division of Rheumatology, San Francisco, CA, 17Lupus Foundation of America, Richmond Hill, GA, 18AbbVie, Inc., Lake Bluff, IL, 19AbbVie, Inc., Libertyville, IL, 20Northwell Health, Great Neck, NY, 21Amgen, Inc., Almada, Portugal, 22Bristol Myers Squibb, Lawrencevile, NJ, 23AbbVie, Inc., Worcester, MA, 24Merck KGaA, Darmstadt, Germany, 25UCB Pharma, Slough, United Kingdom, 26AbbVie, Inc., Norristown, PA, 27University of California San Diego, La Jolla, CA, 28Amgen, Inc., Thousand Oaks, CA, 29Biogen International GmbH, Milton, MA, 30AstraZeneca, Gothenburg, Sweden, 31Bristol-Myers Squibb, New York, NY, 32AstraZeneca, Cambridge, United Kingdom, 33Genentech, San Francisco, CA, 34Lupus Foundation of America, Washington, DC, 35Modus Outcomes, Cambridge, MA, 36Oklahoma Medical Research Foundation, Oklahoma City, OK, 37UCB Pharma, Brussels, Belgium, 38University of Pisa, Pisa, Italy, 39Janssen, Flemington, NJ, 40Bristol Myers Squibb, Lawrence Township, NJ, 41Centro Regional de Enfermedades Autoinmunes y Reumáticas, Rosario, Argentina, 42Janssen Research & Development, San Diego, CA, 43Eli Lilly, Carmel, IN, 44Global Clinical Development, Ares Trading SA, an affiliate of Merck KGaA, Darmstadt, Germany,45SDG LLC, West Newton, MA,46AstraZeneca, Sollentuna, Sweden, 47UCB Pharma, Monheim, 48UCB Pharma, Baltimore, MD, 49University of Occupational and Environmental Health, Kitakyusyu Fukuoka, Japan, 50EMD Serono, an affiliate of Merck KGaA, Darmstadt, Germany, 51Amsterdam University Medical Centers, Amsterdam, Netherlands, 52Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, 53University of Pennsylvania and Corporal Michael J. Crescenz VA Medical Center, Philadelphia, PA, 54Janssen Research and Development, LLC, Spring House, PA, 55Monash University, Victoria; Department of Rheumatology, Monash Health, Melbourne, Australia

    Background/Purpose: Most late-phase randomised controlled trials (RCTs) of novel drugs for systemic lupus erythematosus (SLE) have failed to meet their primary endpoint or shown contradictory…
  • Abstract Number: 2055 • ACR Convergence 2022

    SRI-4 and BICLA: How Well Do They Agree Across Trials of Active Systemic Lupus Erythematosus?

    Alfredo Aguirre1, Mimi Kim2, Kosalaram Goteti3, Ying Li3, Amy Kao4, Nathalie Franchimont5, George Kong5, Catherine Barbey6, Qing Zuraw7, Robert Gordon7, David Manner8, Maria Silk9, Teodora Staeva10, Hoang Nguyen11, Richard Furie12, Matthew Linnik13 and Maria Dall'Era14, 1University of California, San Francisco, San Francisco, CA, 2Albert Einstein College of Medicine, Larchmont, NY, 3EMD Serono, Boston, MA, 4EMD Serono, Billerica, MA, 5Biogen, Cambridge, MA, 6Biogen, Baar, Switzerland, 7Janssen Research and Development, LLC, Spring House, PA, 8Eli Lilly and Company, Indianapolis, IN, 9Eli Lilly, Carmel, IN, 10Lupus Research Alliance, New York, NY, 11Lupus Research Alliance, Houston, TX, 12Northwell Health, Great Neck, NY, 13Eli Lilly and Company, San Diego, CA, 14University of California, Division of Rheumatology, San Francisco, CA

    Background/Purpose: The Systemic Lupus Erythematosus Responder Index 4 (SRI-4) and the British Isles Lupus Assessment Group (BILAG)-based Composite Lupus Assessment (BICLA) are currently the most…
  • Abstract Number: 2049 • ACR Convergence 2022

    ILD Associated with Primary Sjögren’s Syndrome Is Frequently Progressive

    Anna-Maria Hoffmann-Vold1, Håvard Fretheim1, Phoung Phoung Diep1, Karoline Lerang2, Birgir Gudbransson1, Helena Andersson1, Øyvind Midtvedt1, Torhild Garen1, Michael Durheim1, Trond Mogens Aaløkken1, Øyvind Palm1 and Øyvind Molberg2, 1Oslo University Hospital, Oslo, Norway, 2Department of Rheumatology, Oslo University Hospital, Oslo, Norway, Oslo, Norway

    Background/Purpose: Interstitial lung disease (ILD) in primary Sjögren's syndrome (pSS) has been reported to be present in 10-15% of patients, but ILD progression in pSS-ILD…
  • Abstract Number: 2031 • ACR Convergence 2022

    Efficacy and Safety of Telitacicept in Primary Sjögren’s Syndrome: A Randomized, Double-blind, Placebo-controlled, Phase 2 Trial

    Dong Xu1, Shangzhu Zhang1, Cibo Huang2, Chenghui Huang3, Li Qin4, Xiaomei Li5, Meiqing Chen6, Xiumei Liu7, Yi Liu8, Zhijun Li9, Jiankang Hu10, Chunde Bao11, wei Wei12, Jing Tian13, Xinwang Duan14, Jianmin Fang15 and Xiaofeng Zeng16, 1Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China, 2Beijing Hospital, Beijing, China, 3The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, China, 4Huzhou Third Municipal Hospital, Huzhou, China, 5Anhui Provincial Hospital, Hefei, China, 6The First Affiliated Hospital of Xiamen University, Xiamen, China, 7The First Hospital of Shanxi Medical University, Taiyuan, China, 8West China Hospital of Sichuan University, Chengdu, China, 9The First Affiliated Hospital of Bengbu Medical College, Bengbu, China, 10Jiangxi Pingxiang People’s Hospital, Shanghai, China, 11Renji Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Shanghai, China, 12Tianjin Medical University General Hospital, Tianjin, China, 13Second Xiangya Hospital of Central South University, Changsha, China, 14The Second Affiliated Hospital of Nanchang University, Nanchang, China, 15Shanghai Tongji Hospital, Shanghai, China, 16Department of Rheumatology, Peking Union Medical College Hospital (PUMCH), Chinese Academy of Medical Sciences National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Beijing, China

    Background/Purpose: To evaluate the efficacy and safety of telitacicept in adult patients with primary Sjögren’s syndrome (pSS) in a phase II randomized double-blind placebo-controlled trial.Methods:…
  • Abstract Number: 2032 • ACR Convergence 2022

    Major Salivary Gland Ultrasound and Elastography for Assessment of Disease Activity in Patients of Primary Sjögren’s Syndrome

    Kunal Chandwar1, Juhi Dixit1, Kriti Kishor1, DOGGA PRASANNA KUMAR2, DIGVIJAY EKBOTE3, PUNEET KUMAR1 and Urmila Dhakad1, 1King George's Medical University, Lucknow, India, 2KGMU, LUCKNOW, Uttar Pradesh, India, 3KING GEORGE MEDICAL UNIVERSITY, LUCKNOW, Uttar Pradesh, India

    Background/Purpose: To assess major salivary gland involvement by ultrasonography and elastography in patients with Sjögren's syndrome , compare it with controls and correlate the severity…
  • Abstract Number: 2041 • ACR Convergence 2022

    Single Cell Atlas of Minor Salivary Glands Reveals Key Differential Cellular and Functional Players in Sjögren’s and Sicca Syndrome

    SABA NAYAR1, Jason D. turner1, Saba Asam1, Charlotte G. Smith1, Serena Colfrancesco2, Ana Teodósio1, Joe Flint1, David H Gardner1, Professor Simon Bowman3, Adam Croft1, Andrew Filer1, Benjamin A. Fisher1, Christopher Buckley4 and Francesca Barone5, 1University of Birmingham, Birmingham, United Kingdom, 2University of Rome, Rome, Italy, 3University Hospitals Birmingham, Birmingham, United Kingdom, 4University of Oxford, Oxford, United Kingdom, 5University of Birmingham, Needham, MA

    Background/Purpose: Sjögren's syndrome (SjS) shares a series of symptoms with non-SjS Sicca syndrome, a salivary gland disease characterised by glandular dysfunction and dryness. However, unlike…
  • Abstract Number: 1879 • ACR Convergence 2022

    Analysis of the Association Between the Atrophic Factors Tripartite Motif Containing (TRIM) 63 and Atrogin-1 and the Clinical and Inflammatory Features of Patients with Idiopathic Inflammatory Myopathies

    jiram torres-Ruiz1, Abdiel Absalón-Aguilar2, Juan Alberto Reyes-Islas2, Alfredo Pérez-Fragoso2, Nancy R Mejía-Domínguez3, guillermo Juárez-Vega4, Alejandro Alfaro-Goldaracena5, Beatriz Alcalá-Carmona2, Guillermo Juárez-Vega3, Fabiola Cassiano-Quezada2 and Diana Gómez-Martín1, 1INCMNSZ, Ciudad de México, Mexico, 2Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Ciudad de México, Mexico, 3Red de Apoyo a la Investigación, Universidad Nacional Autónoma de México, Ciudad de México, Mexico, 4Red de Apoyo a la Investigación. UNAM, Ciudad de México, Mexico, 5Department of Surgery, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Ciudad de México, Mexico

    Background/Purpose: Muscle atrophy is mediated by the ubiquitination of myofilaments by two ubiquitin ligases called Tripartite Motif Containing (TRIM) 63 and Atrogin-1, which are induced…
  • Abstract Number: 2034 • ACR Convergence 2022

    What Is the Best Initial Screening for Suspected Sjögren’s Disease?

    Katja Perdan Pirkmajer, Jelka Kramarič, matija Tomšič and Alojzija Hocevar, University Medical Centre Ljubljana, Ljubljana, Slovenia

    Background/Purpose: During the COVID-19 pandemic the routine diagnostic procedure in Sjögren's disease (SS) was highly hampered. The aim of our study was to determine in…
  • Abstract Number: 2052 • ACR Convergence 2022

    Vaccine Uptake in Women with Systemic Lupus Erythematosus (SLE) in a Large Urban Teaching Hospital Serving a High-Risk Population

    J. Patricia Dhar1, Forsythe Hannah2, Louis Saravolatz3 and Susanna Szpunar4, 1Ascension St. John Hospital and Wayne State University School of Medicine, Bloomfield Hills, MI, 2Michigan Department of Human and Health Services, Lansing, MI, 3Ascension St John Hospital and Medical Center, Wayne State University School of Medicine (affiliate), Grosse Pointe Woods, MI, 4Ascension St. John Hospital, Grosse Pointe Woods, MI

    Background/Purpose: Infections are a major cause of morbidity & mortality in patients with systemic lupus erythematosus (SLE), including vaccine-preventable infections. SLE patients are considered to…
  • Abstract Number: 2044 • ACR Convergence 2022

    Abnormalities of Extracellular Matrix Modeling Gene Expression in Salivary Gland Epithelial Cells of Patients with Sjögren’s Syndrome

    Elodie Riviere1, Juliette Pascaud1, Franck Letourneur2, Gaetane Nocturne3 and Xavier Mariette4, 1Université Paris-Saclay, INSERM U1184, Le Kremlin Bicêtre, France, 2Genomic, Hôpital Cochin, Université Paris Descartes, Sorbonne Paris Cité, Paris, France, 3APHP, Le Kremlin Bicêtre, France, 4Paris-Saclay University, Rueil Malmaison, Ile-de-France, France

    Background/Purpose: Salivary gland epithelial cells (SGECs) are not only the target of autoimmunity in primary Sjögren's syndrome (pSS). SGECs may interact with lymphocytes and therefore…
  • Abstract Number: 2036 • ACR Convergence 2022

    Development of Systemic Sclerosis in Patients with Primary Sjogren Syndrome and Raynauds Phenomenon

    Andres Martinez1, Julieta Morbiducci1, Constanza Arguissain1, Maria Tamborenea1, Marisel Bejarano2, Lucia Castorino1 and Anastasia Secco1, 1Rivadavia Hospital, Buenos Aires, Argentina, 2Rivadavia´s Hospital, Buenos Aires, Argentina

    Background/Purpose: Primary Sjögren's Syndrome (pSS) is an autoimmune disease, and Raynaud's Phenomenon (RP) is an extraglandular manifestation that can evolve into a systemic sclerosis-overlap syndrome.…
  • Abstract Number: 2038 • ACR Convergence 2022

    Single Cell RNA Sequencing Points to a Role for Fibroblasts Early in Salivary Gland Dysfunction in Primary Sjögren’s Syndrome

    Sarah Pringle1, Fred Spijkervet1, Arjan Vissink2, Hendrika Bootsma1 and Frans Kroese1, 1University Medical Center Groningen, Groningen, Netherlands, 2UMCG, Leek, Netherlands

    Background/Purpose: Salivary gland (SG) dysfunction is commonly associated with the autoimmune disease primary Sjögren's syndrome (pSS). Whilst the more advanced stages of the disease are…
  • « Previous Page
  • 1
  • …
  • 419
  • 420
  • 421
  • 422
  • 423
  • …
  • 2425
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology